{"id":70012,"date":"2026-04-13T12:14:25","date_gmt":"2026-04-13T06:44:25","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=70012"},"modified":"2026-04-13T12:14:27","modified_gmt":"2026-04-13T06:44:27","slug":"blogs-cipla-target-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/","title":{"rendered":"Cipla Share Price Target 2026: Analyst Consensus, Bull Case &amp; Bear Case"},"content":{"rendered":"<p>Cipla (Pharmaceuticals \/ Specialty) is trading at Rs 1,420 as of April 2026, with a 52-week range from Rs 1,250 to Rs 1,750 and a 1-year return of -10%. The analyst consensus 12-month Cipla share price target stands at Rs 1,650-1,900 \u2014 implying meaningful potential movement from current levels.<\/p><p>Whether you are a long-term holder reassessing your position or a new investor evaluating entry levels, understanding where analysts see Cipla heading over the next 12-24 months requires looking beyond the CMP. This article covers the key catalysts and risks, technical levels, institutional positioning, and a structured breakdown of the short-term, 12-month, and long-term Cipla share price targets.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here \u2014 Get Free Investment Predictions on Univest<\/strong><\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Cipla_Key_Data_%E2%80%94_CMP_Valuation_Fundamentals\" title=\"Cipla Key Data \u2014 CMP, Valuation, Fundamentals\">Cipla Key Data \u2014 CMP, Valuation, Fundamentals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Cipla_Share_Price_Targets_%E2%80%94_Short-Term_12-Month_Long-Term\" title=\"Cipla Share Price Targets \u2014 Short-Term, 12-Month &amp; Long-Term\">Cipla Share Price Targets \u2014 Short-Term, 12-Month &amp; Long-Term<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Bull_Case_%E2%80%94_What_Has_to_Go_Right_for_Cipla\" title=\"Bull Case \u2014 What Has to Go Right for Cipla\">Bull Case \u2014 What Has to Go Right for Cipla<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#1_US_generic_launches\" title=\"1. US generic launches\">1. US generic launches<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#2_India_prescription_market_leadership_in_respiratory_therapy\" title=\"2. India prescription market leadership in respiratory therapy\">2. India prescription market leadership in respiratory therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#3_South_Africa_and_sub-Saharan_Africa_branded_generics_business_growing_12-15_annually\" title=\"3. South Africa and sub-Saharan Africa branded generics business growing 12-15% annually\">3. South Africa and sub-Saharan Africa branded generics business growing 12-15% annually<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#4_Peptide_API_capability_GLP-1_semaglutide_generic\" title=\"4. Peptide API capability (GLP-1 semaglutide generic\">4. Peptide API capability (GLP-1 semaglutide generic<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#5_Manufacturing_infrastructure_compliant\" title=\"5. Manufacturing infrastructure compliant\">5. Manufacturing infrastructure compliant<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Bear_Case_%E2%80%94_Key_Risks_to_the_Cipla_Share_Price_Target\" title=\"Bear Case \u2014 Key Risks to the Cipla Share Price Target\">Bear Case \u2014 Key Risks to the Cipla Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Risk_1_Revlimid_authorised_generic_revenue_declining_as_the_exclusivity_window_narrows_and_competition_intensifies\" title=\"Risk 1: Revlimid authorised generic revenue declining as the exclusivity window narrows and competition intensifies\">Risk 1: Revlimid authorised generic revenue declining as the exclusivity window narrows and competition intensifies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Risk_2_Promoters_relatively_low_336_ownership_raising_succession_and_strategic_direction_questions\" title=\"Risk 2: Promoter&#8217;s relatively low 33.6% ownership raising succession and strategic direction questions\">Risk 2: Promoter&#8217;s relatively low 33.6% ownership raising succession and strategic direction questions<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Institutional_Sentiment_and_Technical_Analysis\" title=\"Institutional Sentiment and Technical Analysis\">Institutional Sentiment and Technical Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Conclusion_%E2%80%94_Our_View_on_name_Share_Price_Target\" title=\"Conclusion \u2014 Our View on ${name} Share Price Target\">Conclusion \u2014 Our View on ${name} Share Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Q1_What_is_Cipla_share_price_target_2026\" title=\"Q1. What is Cipla share price target 2026?\">Q1. What is Cipla share price target 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Q2_Is_Cipla_a_good_buy_now\" title=\"Q2. Is Cipla a good buy now?\">Q2. Is Cipla a good buy now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Q3_What_is_Ciplas_current_valuation\" title=\"Q3. What is Cipla&#8217;s current valuation?\">Q3. What is Cipla&#8217;s current valuation?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Q4_What_are_the_key_risks_for_Cipla\" title=\"Q4. What are the key risks for Cipla?\">Q4. What are the key risks for Cipla?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Q5_Where_can_I_track_Cipla_share_price_live\" title=\"Q5. Where can I track Cipla share price live?\">Q5. Where can I track Cipla share price live?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/blogs-cipla-target-share-price-target-2026\/#Recent_Articles\" title=\"Recent Articles\">Recent Articles<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cipla_Key_Data_%E2%80%94_CMP_Valuation_Fundamentals\"><\/span><strong>Cipla Key Data \u2014 CMP, Valuation, Fundamentals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Parameter<\/strong><\/td><td><strong>Value<\/strong><\/td><\/tr><tr><td>CMP (April 2026)<\/td><td>Rs 1,420<\/td><\/tr><tr><td>52-Week High<\/td><td>Rs 1,750<\/td><\/tr><tr><td>52-Week Low<\/td><td>Rs 1,250<\/td><\/tr><tr><td>1-Year Return<\/td><td>-10%<\/td><\/tr><tr><td>Trailing P\/E<\/td><td>28x<\/td><\/tr><tr><td>Price-to-Book<\/td><td>4.8x<\/td><\/tr><tr><td>Market Cap<\/td><td>Rs 1.1L Cr<\/td><\/tr><tr><td>Sector<\/td><td>Pharmaceuticals \/ Specialty<\/td><\/tr><tr><td>Promoter Holding<\/td><td>33.6%<\/td><\/tr><tr><td>FII Holding<\/td><td>20.4%<\/td><\/tr><tr><td>DII Holding<\/td><td>22.6%<\/td><\/tr><\/tbody><\/table><\/figure><p>Track live <strong>Cipla<\/strong> fundamentals and analyst ratings on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cipla_Share_Price_Targets_%E2%80%94_Short-Term_12-Month_Long-Term\"><\/span><strong>Cipla Share Price Targets \u2014 Short-Term, 12-Month &amp; Long-Term<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Access premium analyst research on Univest<\/strong><\/a>.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Scenario<\/strong><\/td><td><strong>Target<\/strong><\/td><td><strong>Basis<\/strong><\/td><\/tr><tr><td>Short-Term (3-6M)<\/td><td>Rs 1,650<\/td><td>Technical support; near-term catalyst<\/td><\/tr><tr><td>12-Month Consensus<\/td><td>Rs 1,650-1,900<\/td><td>Analyst consensus based on current fundamentals<\/td><\/tr><tr><td>Bull Case (FY28)<\/td><td>Rs 2,300<\/td><td>Full execution of growth catalysts below<\/td><\/tr><tr><td>Bear Case<\/td><td>Rs 1,100<\/td><td>Materialisation of key risks below<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bull_Case_%E2%80%94_What_Has_to_Go_Right_for_Cipla\"><\/span><strong>Bull Case \u2014 What Has to Go Right for Cipla<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_US_generic_launches\"><\/span><strong>1. US generic launches<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Revlimid (lenalidomide) authorised generic contributing Rs 1,000+ crore annualised at current run rate<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_India_prescription_market_leadership_in_respiratory_therapy\"><\/span><strong>2. India prescription market leadership in respiratory therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Cipla&#8217;s inhaler brand (Cipla Medpro) is a genuine moat<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_South_Africa_and_sub-Saharan_Africa_branded_generics_business_growing_12-15_annually\"><\/span><strong>3. South Africa and sub-Saharan Africa branded generics business growing 12-15% annually<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>South Africa and sub-Saharan Africa branded generics business growing 12-15% annually<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Peptide_API_capability_GLP-1_semaglutide_generic\"><\/span><strong>4. Peptide API capability (GLP-1 semaglutide generic<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>future opportunity) creating next-generation API business<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Manufacturing_infrastructure_compliant\"><\/span><strong>5. Manufacturing infrastructure compliant<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>no outstanding FDA 483s or warning letters across key facilities<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bear_Case_%E2%80%94_Key_Risks_to_the_Cipla_Share_Price_Target\"><\/span><strong>Bear Case \u2014 Key Risks to the Cipla Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_1_Revlimid_authorised_generic_revenue_declining_as_the_exclusivity_window_narrows_and_competition_intensifies\"><\/span><strong>Risk 1: Revlimid authorised generic revenue declining as the exclusivity window narrows and competition intensifies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Revlimid authorised generic revenue declining as the exclusivity window narrows and competition intensifies<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_2_Promoters_relatively_low_336_ownership_raising_succession_and_strategic_direction_questions\"><\/span><strong>Risk 2: Promoter&#8217;s relatively low 33.6% ownership raising succession and strategic direction questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Promoter&#8217;s relatively low 33.6% ownership raising succession and strategic direction questions<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Institutional_Sentiment_and_Technical_Analysis\"><\/span><strong>Institutional Sentiment and Technical Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Cipla has 20.4% FII holding and 22.6% DII holding. High FII ownership of 20.4% means the stock is sensitive to global risk-off events \u2014 FII selling can be disproportionate to any specific negative news.<\/p><p>Technically, Cipla is trading at Rs 1,420 against a 52-week range of Rs 1,250 to Rs 1,750. The -10% 1-year return positions the stock in negative territory \u2014 creating both risk of further downside and opportunity for mean reversion. The 12-month analyst target of Rs 1,650-1,900 implies the stock is expected to recover meaningfully from current depressed levels.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> for real-time research and analyst updates.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion_%E2%80%94_Our_View_on_name_Share_Price_Target\"><\/span><strong>Conclusion \u2014 Our View on ${name} Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Cipla at Rs 1,420 is a quality pharma stock at a reasonable valuation. The US business (Revlimid contribution + complex generics pipeline), India respiratory leadership, and clean regulatory track record provide a quality platform. At 28x P\/E, the stock is not cheap but not expensive for the quality of earnings. 12-month target of Rs 1,650-1,900 implies 16-34% upside.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Subscribe to Univest Pro for SEBI-registered analyst recommendations \u2014 entry, target, stop-loss.<\/strong><\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q1_What_is_Cipla_share_price_target_2026\"><\/span><strong>Q1. What is Cipla share price target 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Cipla share price target for 2026 is Rs 1,650-1,900 based on analyst consensus. The bull case target is Rs 2,300 and the bear case is Rs 1,100. These are analyst estimates, not guaranteed returns.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q2_Is_Cipla_a_good_buy_now\"><\/span><strong>Q2. Is Cipla a good buy now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Cipla is trading at Rs 1,420 against a 52-week range of Rs 1,250 to Rs 1,750. Analyst consensus target of Rs 1,650-1,900 implies upside from current levels. Consult a SEBI-registered financial advisor before investing.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q3_What_is_Ciplas_current_valuation\"><\/span><strong>Q3. What is Cipla&#8217;s current valuation?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Cipla trades at a trailing P\/E of 28x and price-to-book of 4.8x with a market capitalisation of Rs 1.1L Cr. The stock&#8217;s valuation relative to earnings growth determines the appropriate entry point.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q4_What_are_the_key_risks_for_Cipla\"><\/span><strong>Q4. What are the key risks for Cipla?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Key risks for Cipla include the factors outlined in the Bear Case section of this article. Revlimid authorised generic revenue declining as the exclusivity window narrows and competition intensifies is the primary near-term risk to watch.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q5_Where_can_I_track_Cipla_share_price_live\"><\/span><strong>Q5. Where can I track Cipla share price live?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Track Cipla share price live, quarterly results, FII\/DII activity, and analyst ratings on the Univest Screener at univest.in\/screeners. Download the Univest iOS or Android App for daily research.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All analyst targets are estimates and may change. Verify all numbers before investing. Consult a SEBI-registered financial advisor before making any investment decisions.<\/p><p>For more stock research, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Articles\"><\/span>Recent Articles<span class=\"ez-toc-section-end\"><\/span><\/h2><p>&nbsp;<a href=\"https:\/\/univest.in\/blogs\/why-is-krbl-share-price-falling\"><strong>Why is KRBL Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-reliance-infrastructures-share-price-falling\"><strong>Why is Reliance Infrastructures Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-mahanagar-gas-share-price-falling\"><strong>Why is Mahanagar Gas Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-happiest-minds-share-price-falling\"><strong>Why is Happiest Minds Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Cipla (Pharmaceuticals \/ Specialty) is trading at Rs 1,420 as of April 2026, with a 52-week range from Rs 1,250 to Rs 1,750 and a 1-year return of -10%. The analyst consensus 12-month Cipla share price target stands at Rs 1,650-1,900 \u2014 implying meaningful potential movement from current levels. Whether you are a long-term holder<\/p>\n","protected":false},"author":26,"featured_media":70014,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-70012","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"_edit_lock":["1776062726:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["842"],"rank_math_seo_score":["77"],"rank_math_focus_keyword":["Cipla"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"rank_math_title":["Cipla Share Price Target 2026: Analyst Estimates, Bull &amp; Bear Case"],"rank_math_description":["Cipla share price target 2026 \u2014 analyst consensus Rs 1,650-1,900. CMP Rs 1,420, 12M target, bull case Rs 2,300, bear case Rs 1,100. Full analysis.\n"],"_thumbnail_id":["70014"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7863"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13121327\/cipla-target_.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=70012"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70012\/revisions"}],"predecessor-version":[{"id":70016,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70012\/revisions\/70016"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/70014"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=70012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=70012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=70012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}